ライフサイエンスコーパス: Affymetrix

1 d using whole-genome expression microarrays (Affymetrix).

2 analyzed by U133 Plus 2.0 expression array (Affymetrix).

3 nscriptome analysis with Gene 1.1 ST Arrays (Affymetrix).

4 By using Affymetrix 10K chip, we established linkage to chromosom

5 le brain gene expression data (gathered with Affymetrix 430 v2 arrays in the Colorado laboratories) a

6 profiling of PI stimulation was performed on Affymetrix 430A chips, and CN was inhibited via FK506.

7 600 German AgP cases, 1448 controls) and the Affymetrix 500K array set (283 German AgP cases and 972

8 Despite the fact that the SNPs of the Affymetrix 500k chip were ascertained with a bias toward

9 Using the Affymetrix 500K Mapping array and publicly available gen

10 10-Quad arrays and 112 Mexicans genotyped on Affymetrix 500K platform.

11 ic structure, we obtained and genotyped with Affymetrix 500k SNP arrays DNA samples from 168 self-rep

12 Germline DNA was genotyped using the Affymetrix 500K, Affymetrix 6.0, or the Illumina Exome B

13 eart Study (FHS) participants genotyped with Affymetrix 550K SNPs, we imputed genotypes of same set o

14 of 144 mitochondrial markers as well as the Affymetrix 6.0 (n = 432), Illumina 610-Quad (n = 458), o

15 s for Myopia (SCORM) and simulated data from Affymetrix 6.0 and platform-independent distributions.

16 formed a genome-wide association study using Affymetrix 6.0 array and imputed genotype data.

17 from single-nucleotide polymorphisms from an Affymetrix 6.0 array and we used Cox proportional hazard

18 estry informative markers from a genome-wide Affymetrix 6.0 array in ARIC African Americans yielded s

19 eotide polymorphism (SNP) data utilizing the Affymetrix 6.0 array with imputation to 2.5 million HapM

20 ial single nucleotide polymorphisms from the Affymetrix 6.0 array.

21 Homozygosity mapping using the Affymetrix 6.0 chips demonstrates that all 6 GPS-affecte

22 single-nucleotide polymorphisms based on an Affymetrix 6.0 Gene Chip dataset of 564 German sarcoidos

23 anced AMD cases and 1,709 controls using the Affymetrix 6.0 platform with replication in seven additi

24 Genotyping was performed on the Affymetrix 6.0 platform.

25 739 healthy controls were genotyped with the Affymetrix 6.0 single nucleotide polymorphism (SNP) arra

26 discovery group (n=428) was performed using Affymetrix 6.0 Single-Nucleotide Polymorphism (SNP) Arra

27 d genomic aberrations in PEL cells using the Affymetrix 6.0 SNP array.

28 We used Affymetrix 6.0 SNP arrays to survey common CNVs in a coh

29 orphism genotyping arrays (Illumina 660W and Affymetrix 6.0) and multiplex ligation-dependent probe a

30 DNA was genotyped using the Affymetrix 500K, Affymetrix 6.0, or the Illumina Exome BeadChip array.

31 tested the cross-species application of the Affymetrix 600K Chicken SNP array in five species of Nor

32 However, Illumina and Affymetrix algorithms that leverage single nucleotide po

33 was among the top ten upregulated genes upon Affymetrix analysis.

34 agreement between results obtained using the Affymetrix and Agilent platforms.

35 ation (n = 66) profiles were generated using Affymetrix and Illumina arrays, respectively.

36 tina controls (n= 1272) were genotyped using Affymetrix and Illumina arrays.

37 Affymetrix and Illumina Omni 2.5 platforms were used to

38 leotide polymorphism (SNP) markers from both Affymetrix and Illumina platforms were assayed for all 2

39 Data from Affymetrix and Illumina studies were jointly analyzed wi

40 -derived classifiers were tested on separate Affymetrix- and Illumina-based experiments, and collated

41 is was performed from breathing tumors by an Affymetrix approach.

42 Affymetrix array analyses of cultured fibroblasts identi

43 Affymetrix Array experiments revealed 24 differentially

44 Affymetrix array profiling of cDNAs from the osteosarcom

45 Affymetrix array showed a global perturbation in the exp

46 valuated at the RNA and protein levels using Affymetrix array, real-time PCR, and immunoassays.

47 Expression profiling was performed using Affymetrix arrays on total RNA.

48 olysomal RNA-based expression profiling with Affymetrix arrays revealed extensive changes in the tran

49 ed network analysis of lung transcriptomics (Affymetrix arrays) in 70 former smokers with COPD to com

50 Genotyping was done using Affymetrix arrays, augmented by imputation.

51 Transcriptional profiling was performed with Affymetrix arrays, Principal Component Analysis and the

52 ene expression profiles were evaluated using Affymetrix arrays.

53 The transcriptome was determined using Affymetrix arrays.

54 that uses the noise distribution present in Affymetrix arrays.

55 y, genome-wide expression profiling based on Affymetrix ATH1 arrays was used to identify discriminati

56 me network of Arabidopsis thaliana from 3137 Affymetrix ATH1 GeneChips in just 9 min on a 1024-core c

57 Here, we reanalyzed a total of 79 Affymetrix ATH1 microarray studies of redox homeostasis

58 Transcriptome analysis using the Affymetrix ATH1 platform has been completed on purified

59 (UBC9, SAND, PTB, and F-box) identified from Affymetrix ATH1 whole-genome GeneChip studies.

60 Genotyping was performed using the Affymetrix Axiom and illumina 1 M arrays.

61 cases and 54,566 controls) genotyped on the Affymetrix Axiom European array and a replication phase

62 microarray based on the new highly-efficient Affymetrix Axiom genotyping technology that we are using

63 the development and validation of a 487K SNP Affymetrix Axiom((R)) genotyping array for apple and dis

64 enome-wide association study (SNP Array 6.0, Affymetrix, CA, USA) of NTS bacteraemia in Kenyan childr

65 Utilizing the Affymetrix canine microarray, we are able to definitivel

66 Affymetrix cDNA microarray analysis was conducted to ide

67 An Affymetrix cDNA microarray chip (Pvi_cDNAa520831) contai

68 Analysis of raw microarray data files (e.g. Affymetrix CEL files) can be time consuming, complex, an

69 Using an Affymetrix chip with imputation to 2.5 M single-nucleoti

70 oSpyder TempO-Seq, Ion AmpliSeq, Nanostring, Affymetrix Clariom S or U133A, Illumina BeadChip and RNA

71 present the R package affy2sv to pre-process Affymetrix CytoScan HD/750k array (also for Genome-Wide

72 addition, previously published L. japonicus Affymetrix data are included in the database, making it

73 After adjusting Affymetrix data to mimic the Agilent experimental design

74 For Affymetrix data, the strongest signal for DBP was rs1047

75 btained by hybridization of messenger RNA to Affymetrix Drosophila Genome 2 microarrays.

76 Gene expression was assessed with the Affymetrix Exon Array.

77 and AS profiles of 43 pancreas tissues using Affymetrix exon array.

78 We compared previously perform Affymetrix expression analysis in a subset of samples an

79 By Affymetrix expression analysis, we show that the cytochr

80 Analysis of Affymetrix expression array data revealed that high leaf

81 Affymetrix expression arrays were used to identify diffe

82 We used the 47K GeneChip U133 Plus 2.0 Affymetrix expression microarray platform to obtain re-e

83 testicular germ cell tumor cell lines using Affymetrix expression microarrays and revealed a limited

84 and silver ions (Ag(+)) were analyzed using Affymetrix expression microarrays.

85 The Affymetrix-focused BaFL pipeline takes into account prob

86 targets of miR-192/-194 in vivo we combined Affymetrix gene analysis of liver in which miR-192/-194

87 hickness by histology and gene expression by Affymetrix gene arrays and PCR in the skin of 10 obese (

88 sue Expression (GTEx) project, consisting of Affymetrix gene arrays and RNA-Seq from over 700 samples

89 mRNA expression was measured by Affymetrix gene chips, and differences were analyzed by

90 100PBP were generated and investigated using Affymetrix gene expression arrays and complementary func

91 ed analysis of MethylCap-sequencing data and Affymetrix gene expression microarray data for 30 breast

92 itive element probes present in Illumina and Affymetrix gene expression microarray platforms can accu

93 by the GoldenGate methylation BeadArray and Affymetrix gene expression platforms in 193 MM samples.

94 In this study, we used Affymetrix GeneChip (Affymetrix) to globally assess the

95 A genome-wide association study using Affymetrix GeneChip 100K arrays was performed in a disco

96 ome-wide perspective of ancestry, we analyze Affymetrix GeneChip 500K genotype data from African Amer

97 Affymetrix GeneChip 6.0 DNA arrays were used to genotype

98 The adipogenic capacity was measured by Affymetrix GeneChip and quantitative RT-PCR.

99 microarray data set using the Human HG_U133A Affymetrix GeneChip and RMA normalization there is signi

100 rstand the reactive astrocyte state, we used Affymetrix GeneChip arrays to profile gene expression in

101 An Affymetrix GeneChip consists of an array of hundreds of

102 An analysis of published Affymetrix GeneChip data to detect downstream effectors

103 ridization was conducted as described in the Affymetrix GeneChip Expression Analysis Technical Manual

104 en genome and the subsequent availability of Affymetrix GeneChip genome arrays, several laboratories

105 Galician (northwest Spain) samples using the Affymetrix GeneChip Human 20k cSNP Kit, followed by a re

106 Whole blood samples were assayed by Affymetrix GeneChip Human Genome U133 Plus 2.0 Array.

107 iopsies from 18 breast cancer patients using Affymetrix GeneChip Human Genome U133 Plus 2.0 arrays.

108 cells were compared between groups using the Affymetrix GeneChip hybridization protocol and hierarchi

109 d, the isolated RNA can be used directly for Affymetrix GeneChip labeling or real-time RT-PCR without

110 Genome-wide linkage analysis using Affymetrix GeneChip Mapping 10K data from 12 affected me

111 ation period and examined the transcripts by Affymetrix GeneChip microarray before gastrulation.

112 The Affymetrix GeneChip microarray is currently providing a

113 Affymetrix GeneChip microarrays are the most widely used

114 xpression normalization algorithms exist for Affymetrix GeneChip microarrays.

115 years) and 9 matched controls using both the Affymetrix GeneChip miRNA 2.0 and Human Exon 1.0 ST Arra

116 iRNA expression profiling was performed with Affymetrix GeneChip miRNA 3.0 arrays; and results were v

117 serving as controls were analyzed using the Affymetrix GeneChip miRNA Array.

118 Microarrays were performed using the Affymetrix GeneChip Mouse Genome 430A 2.0 Array.

119 alysed for gene expression by a high-density Affymetrix GeneChip platform, encompassing more than 1 m

120 m >28 000 CEL files relating to 10 different Affymetrix GeneChip platforms and involving nearly 1000

121 paper, we examined the effect of the SNPs on Affymetrix GeneChip probe set summaries and the expressi

122 ver RNA was isolated and microarrayed on the Affymetrix GeneChip Rat Exon 1.0 ST array.

123 wing ischemia/reperfusion was examined using Affymetrix GeneChip technology.

124 e performed transcriptome analysis using the Affymetrix GeneChip U133A in gastric cardia adenocarcino

125 d platforms for gene expression microarrays, Affymetrix GeneChip(R) arrays, have as many as ten or mo

126 NanoString nCounter(R) and Affymetrix GeneChip(R) Human Transcriptome Array 2.0 (HT

127 nt, including those unique to seeds, we used Affymetrix GeneChips to profile Arabidopsis genes active

128 We propose a new filtering strategy for Affymetrix GeneChips(R), based on principal component an

129 RNA was processed and hybridized to Affymetrix GeneChips, to determine expression of over 47

130 , have provided insights for the analysis of Affymetrix GeneChips.

131 ol, and participants were genotyped with the Affymetrix Genome-Wide Human SNP 6.0 Array.

132 ects of Mexican ancestry genotyped using the Affymetrix Genome-Wide Human SNP array 5.0.

133 nd an Indian-origin rhesus macaque using the Affymetrix Genome-Wide Human SNP Array 6.0 and cataloged

134 t in the general ASD population, we used the Affymetrix genome-wide human SNP array 6.0 to identify 1

135 We used the Affymetrix Genome-Wide Human SNP Array 6.0 to test for a

136 sequence oligonucleotide arrays are applied (Affymetrix Genome-Wide Human SNP Array 6.0) by evaluatin

137 sing the Illumina Human610-Quad Beadchip and Affymetrix Genome-Wide Human SNP Array 6.0.

138 ed for genomic copy-number variants with the Affymetrix Genome-wide Human SNP Array 6.0.

139 nd local controls (n = 658) genotyped on the Affymetrix Genome-Wide SNP 6.0 Array, along with 2,400 o

140 BAVM cases and 1191 controls genotyped using Affymetrix genome-wide SNP arrays.

141 ral pathway related genes represented on the Affymetrix Grape Genome array indicated 60 were signific

142 Affymetrix has recently developed whole-transcript GeneC

143 ation, and gene expression was assessed with Affymetrix HG-U133 Plus 2.0 GeneChips.

144 Within GEO, the Affymetrix HG-U133A and HG-U133 Plus 2.0 are the two mos

145 Gene expression data were generated using Affymetrix HG-U133Plus2.0 microarrays.

146 5 nonpsoriatic) samples were examined using Affymetrix HG-U95A microarrays.

147 The Affymetrix HGU133plus2 microarray platform was employed

148 Using a microarray analysis (Affymetrix, High Wycombe, UK), we compared transcriptome

149 al brushings (n = 65) and biopsies (n = 47) (Affymetrix HT HG-U133+ PM).

150 and used Illumina human HT-12 v4 arrays and Affymetrix HTA 2.0 arrays to generate global gene expres

151 RASA was demonstrated with Affymetrix HTAs and its performance was evaluated with m

152 n-lesional sites (n=10) of AA patients using Affymetrix Hu95A-v2 arrays.

153 plant kidney biopsy samples were analyzed by Affymetrix HuGene 1.0 ST expression arrays.

154 s in a subset of patients were studied using Affymetrix HuGene 1.0ST arrays.

155 ood gene expression profiles were studied by Affymetrix Human 1.0 ST GeneChips before and after treat

156 ve nonneoplastic prostate samples, using the Affymetrix Human Array GeneChip Exon 1.0 ST.

157 ay, which uses 50-mer probes, and exon-based Affymetrix Human Exon 1.0 ST array, which uses 25-mer pr

158 ramingham Heart Study Offspring Cohort using Affymetrix Human Exon 1.0 ST Array.

159 plicing were profiled over 12 days using the Affymetrix Human Exon 1.0 ST Array.

160 nd 23 healthy controls (HC) was processed on Affymetrix Human Exon 1.0 ST arrays.

161 We assessed the NCI-60 transcriptome using Affymetrix Human Exon 1.0 ST microarrays and correlated

162 A algorithm to two new microarray platforms--Affymetrix Human Exon and Gene 1.0 ST--by modifying the

163 ptome changes following interrogation of the Affymetrix Human Exon ST 1.0 array.

164 condition with a total of 54 separate human Affymetrix Human Gene 1.0 ST array replicates.

165 with and without BK viremia were analyzed by Affymetrix Human Gene 1.0 ST Arrays.

166 rs with and without COPD was performed using Affymetrix Human Gene 1.0 ST Arrays.

167 88, RNA-seq = 168), and three Asian-cohorts (Affymetrix Human Gene 1.0ST-Array = 61, Illumina = 52, A

168 ene expression profiles were generated using Affymetrix Human Gene 1.1 ST arrays.

169 isolated from PBMCs was hybridized onto the Affymetrix Human Gene 2.0 ST Array.

170 output of microarray hybridization platform Affymetrix Human Gene.

171 age cultures of CAF and NF and analyzed with Affymetrix Human Genome U133 Plus 2.0 arrays.

172 annotated gene probe sets represented on the Affymetrix Human Genome U133 plus 2.0 platform.

173 d transcriptome profiling was performed with Affymetrix Human Genome U219 Plate (Affymetrix, Inc., Sa

174 A 2.0 arrays and for genomic variation using Affymetrix Human Mapping 100 K set.

175 de polymorphisms genotyped using Genome-wide Affymetrix Human SNP Array 6.0 (Affy6.0) and the remaind

176 ed pathway association analysis of KBD using Affymetrix Human SNP Array 6.0 in 1717 Chinese Han subje

177 dChip, Infinium Global Screening Arrays, and Affymetrix Human Transcriptome 2.0 arrays in calcified a

178 We compared Affymetrix Human Transcriptome Arrays, Illumina RNA-Seq,

179 ti-methylcytidine antibodies and detected by Affymetrix human whole genome SNP 6.0 chips.

180 Amplified mRNA was hybridized to an Affymetrix Human X3P array.

181 identified one genome-wide significant hit (Affymetrix id 1:64178756_C_T; P=1.36 x 10(-11)).

182 a across different microarray platforms from Affymetrix, Illumina and Agilent.

183 Agilent platforms outperformed Illumina and Affymetrix in accuracy and precision of copy number dosa

184 ty panels and a combined panel (Illumina and Affymetrix) in Nelore beef cattle.

185 med with Affymetrix Human Genome U219 Plate (Affymetrix, Inc., Santa Clara, CA) and miRNA Chip 2.0.

186 vendors: U95A, U133A and U133 Plus 2.0 from Affymetrix, Inc.; HT-12 v1, HT-12v2 and HT-12v3 from Ill

187 gh-throughput platforms such as Illumina and Affymetrix is a critical step in data processing, so tha

188 odify annotation files for the commonly used Affymetrix IVT and Gene/Exon platforms.

189 ion study in 80 cases and 150 controls using Affymetrix Mapping 10K arrays.

190 ma tumor specimens from Asian patients using Affymetrix messenger RNA (mRNA) and NanoString microRNA

191 Affymetrix MicroArray analyses were conducted on human N

192 Using Affymetrix microarray analyses, the global transcriptome

193 Indeed, Affymetrix microarray analysis and immunocytochemistry i

194 We used Affymetrix microarray analysis and validated differentia

195 Using Affymetrix microarray analysis of 102 breast cancers, we

196 We therefore performed whole mouse genome Affymetrix microarray analysis of pancreatic gene expres

197 Affymetrix microarray analysis revealed that gamma inter

198 from ovarian ascitic fluids were analysed by Affymetrix microarray analysis, immunoblotting, immunohi

199 or profiling messenger RNA expression, using Affymetrix microarray analysis.

200 PBL gene expression was assessed using Affymetrix microarray and was confirmed by quantitative

201 m of phagocytosis, we used an E. histolytica Affymetrix microarray chip to measure the total gene exp

202 facilitate and standardize Meta-Analysis of Affymetrix Microarray Data analysis (MAAMD) in Kepler.

203 tudy design to generate Illumina RNA-seq and Affymetrix microarray data from the same liver samples o

204 ary cultures was determined by FACS analysis.Affymetrix microarray data indicated that NuMA was overe

205 ation bias from experiments performed on the Affymetrix microarray platform, allowing accurate assess

206 r mRNA profiles were then analyzed using the Affymetrix microarray platform, with validation by quant

207 next-generation sequencing, and Illumina and Affymetrix microarray platforms, to compare the transcri

208 In analysis of our Affymetrix microarray profiling and chromatin immunoprec

209 GF-beta3 are abundant in seminal plasma, and Affymetrix microarray revealed that TGF-beta3 elicits ch

210 Affymetrix microarray showed > 90% similarity in gene ex

211 A was processed for use with the full-genome Affymetrix microarray.

212 e embryonic stem (ES) cells with a prototype Affymetrix microarray.

213 t the average correlations between probes on Affymetrix microarrays are larger for smaller chip dista

214 expression using RNAseq in EvA (n = 283) and Affymetrix microarrays in U-BIOPRED (n = 85).

215 r Tools and PennCNV-Affy software to analyze Affymetrix microarrays of the first 152,728 genotyped in

216 g donor rats for global gene expression with Affymetrix microarrays, hepatic tissue integrity, viabil

217 m female C57BL/6 mice, analyzed using 1.0 ST-Affymetrix microarrays, revealed extensive activation of

218 gene expression patterns were profiled using Affymetrix microarrays.

219 with untreated cells (P<0.005; FDR=0), using Affymetrix microarrays.

220 animals responding to LPS was profiled using Affymetrix microarrays.

221 enome-scale polymorphism scan using existing Affymetrix microarrays.

222 gene expression profiles were compared using Affymetrix microarrays.

223 d of patients with asthma was measured using Affymetrix microarrays.

224 Affymetrix miRNA profiling was performed on ML collected

225 rum parasites genotyped using a custom-built Affymetrix molecular inversion probe 3K malaria panel ar

226 Total RNA were extracted and profiled on Affymetrix mouse 430 2.0 micro-arrays.

227 and nontransgenic littermate controls using Affymetrix mouse exon arrays.

228 Using Affymetrix mouse exon-arrays, we identified exons with c

229 Affymetrix Mouse Gene 1.0 ST Array profiles were generat

230 sgenic hearts by Illumina RNA sequencing and Affymetrix Mouse Gene 1.0 ST arrays revealed superior dy

231 and analyzed their global gene expression on Affymetrix Mouse Genome 430A microarrays.

232 GeneChip Affymetrix oligonucleotide arrays were used to assess gl

233 Tumor data analyzed by Affymetrix OncoScan FFPE Assay yielded the log ratio (R)

234 analyzed 971 stage I/II breast tumors using Affymetrix Oncoscan molecular inversion probe arrays tha

235 MM and BAC for the high-resolution data from Affymetrix platform, but significantly outperforms the o

236 ion (GCH) experiment and performed using the Affymetrix platform, contains two different types of pro

237 minantly HBV-positive cases analyzed with an Affymetrix platform, whereas cohort 2 contained 139 case

238 rified CD4 and CD8 TILs was performed on the Affymetrix platform.

239 1.5 million SNPs, generated by Illumina and Affymetrix platforms in a larger set of individuals.

240 different tumour types, profiled on Agilent, Affymetrix platforms or based on RNA sequencing and avai

241 Genotyping was performed on Illumina and Affymetrix platforms with additional markers imputed to

242 array studies on spotted oligonucleotide and affymetrix platforms.

243 Transcriptional profiling on Affymetrix (porcine) microarrays and real time RT-PCR su

244 Data were normalized using Affymetrix Power Tools and analyzed using commercial mic

245 We used Affymetrix Power Tools and PennCNV-Affy software to anal

246 Transcript data may be accessed using the Affymetrix probe identification number, DNA sequence, ge

247 ethylated DNA immunoprecipitation (MeDIP) on Affymetrix promoter chips to interrogate methylation pro

248 tter, and neostriatum was processed with the Affymetrix(R) array platform.

249 hen perform a comprehensive analysis of 3581 Affymetrix(R) gene expression arrays across 17 diverse b

250 Here, Affymetrix(R) GeneChip miRNA version 1 oligonucleotide m

251 hat depend on the distance between probes on Affymetrix(R) microarrays.

252 iduals using a high-density SNP chip (600 K, Affymetrix(R)) to estimate genomic heritability of perfo

253 lysis of human Ensembl transcripts mapped by Affymetrix(R); and Agilent microarray probes.

254 calls the vast majority of SNPs in dbSNP and Affymetrix's Genome-Wide Human SNP Array 6.0 up to about

255 de polymorphism analysis was performed using Affymetrix (Santa Clara, CA) platforms.

256 ing expression pattern (Affymetrix U133 2.0; Affymetrix, Santa Clara, CA), DNA change (Affymetrix STY

257 hybridized with the Human Gene ST 1.0 array (Affymetrix, Santa Clara, CA).

258 P6 genotyping and copy number (CN) analysis (Affymetrix, Santa Clara, CA, USA) were used to determine

259 osexual men and 1,231 heterosexual men using Affymetrix single nucleotide polymorphism (SNP) arrays.

260 opy number aberrations, called CNAnova, from Affymetrix SNP 6.0 array data.

261 genotyped by KASPar assay and US patients by Affymetrix SNP 6.0 array.

262 eimer's disease (AD) using data generated on Affymetrix SNP 6.0 arrays and imputed at over 5.7 millio

263 y, we analyzed copy number aberrations using Affymetrix SNP 6.0 arrays in 60 periampullary adenocarci

264 We profiled 251 genomes using Affymetrix SNP 6.0 arrays to determine copy number varia

265 ber changes and loss of heterozygosity using Affymetrix SNP 6.0 arrays, and we correlated genomic les

266 s analyzed for copy number aberrations using Affymetrix SNP 6.0 arrays.

267 s (aCNAs) with the use of ultra-high-density Affymetrix SNP 6.0 arrays.

268 ma and 26 precancerous lesion patients using Affymetrix SNP 6.0 arrays.

269 blood, and 3 cell lines) were analyzed using Affymetrix SNP 6.0 chips.

270 Genotyping with Affymetrix SNP Array 6.0 was performed on two groups of

271 from a family blood pressure study that used Affymetrix SNP Array 6.0.

272 t of more complex pipelines aimed to analyze Affymetrix SNP arrays data in genetic association studie

273 High-resolution Affymetrix SNP6 genotyping and copy number (CN) analysis

274 ed in peripheral blood with the high-density Affymetrix SNP6.0 microarray platform.

275 yping a known set of variants (e.g. dbSNP or Affymetrix SNPs), is important for characterization of k

276 For Affymetrix SNPs, LAVA has significantly higher SNP calli

277 L15, we assessed the transcriptome using the Affymetrix Soybean Genome Array.

278 0; Affymetrix, Santa Clara, CA), DNA change (Affymetrix STY Mapping Array), mutation (CTNNB1), and im

279 We used custom Affymetrix symbiosis chips to characterize the global tr

280 ranscriptional profile was analyzed by using Affymetrix technology.

281 analysis of gene expression was performed by Affymetrix technology.

282 ing sites using a ChIP-chip approach and the Affymetrix tiling arrays for Arabidopsis thaliana and fo

283 trix) with gene expression array (U133A 2.0; Affymetrix) to examine molecular differences between SSM

284 In this study, we used Affymetrix GeneChip (Affymetrix) to globally assess the host cell genes and p

285 sion was assessed with three data sets using Affymetrix U133 + gene chips on normal human colonic muc

286 for each subclass using expression pattern (Affymetrix U133 2.0; Affymetrix, Santa Clara, CA), DNA c

287 time RT-PCR and 61 kidney biopsies using the Affymetrix U133 array.

288 ononuclear cells (PBMCs) were obtained using Affymetrix U133 Plus 2.0 arrays.

289 and 4 normal adrenal glands were profiled on Affymetrix U133 Plus2 expression microarrays to identify

290 RNA was isolated from blood and run on Affymetrix U133 Plus2.0 microarrays.

291 Affymetrix U133+2.0 human microarray chips were used to

292 omitantly analyzed for gene expression using Affymetrix U133A 2.0 arrays and for genomic variation us

293 s: Three Caucasian-predominant TCGA-cohorts (Affymetrix U133A = 548, Agilent Custom-Array = 588, RNA-

294 Whole-blood RNA was hybridised to Affymetrix U133plus2 microarrays.

295 nucleotide polymorphism-array analysis using Affymetrix Version 6.0 on 353 samples from untreated pat

296 Gene expression analysis (Affymetrix) was performed in MM-MSC and ND-MSC after in

297 ns, using GeneChipp U133 Plus 2 microarrays (Affymetrix), was conducted between October 2012 and Janu

298 omas and 12 sporadic KCOTs was hybridized on Affymetrix whole genome arrays.

299 s single nucleotide polymorphism array (6.0; Affymetrix) with gene expression array (U133A 2.0; Affym

300 Subjects were genotyped on an Affymetrix World Array IV chip.